Literature DB >> 19026147

An update on mortality in systemic lupus erythematosus.

A Ippolito1, M Petri.   

Abstract

OBJECTIVE: Both systemic lupus erythematosus (SLE) and its treatments can contribute to increased mortality rates. The main focus of this review is recent studies on mortality during the last 5 years.
METHODS: A literature search using PUBMED was performed for articles relating to lupus mortality with a specific focus on literature published within the last 5 years.
RESULTS: Survival rates for lupus patients have improved greatly with the ability to treat disease-specific manifestations and infections and to lessen the impact of comorbid conditions. Nonetheless, disparities in mortality rates still exist based on ethnicity, socioeconomic status, age, and gender. Cardiovascular disease, infection, and severe disease activity remain common causes of mortality.
CONCLUSIONS: Despite advances in the treatment of SLE-associated infection, and renal failure, increased mortality remains a major concern in patient management.

Entities:  

Mesh:

Year:  2008        PMID: 19026147

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  40 in total

1.  Therapy: Off-label biologics use and infection risk-the great unknown.

Authors:  Kevin L Winthrop; Josef S Smolen
Journal:  Nat Rev Rheumatol       Date:  2011-10-11       Impact factor: 20.543

2.  Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus.

Authors:  Aimee O Hersh; Laura Trupin; Jinoos Yazdany; Peter Panopalis; Laura Julian; Patricia Katz; Lindsey A Criswell; Edward Yelin
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-08       Impact factor: 4.794

3.  The involvement of T regulatory lymphocytes in a cohort of lupus nephritis patients: a pilot study.

Authors:  Antonella Afeltra; Antonietta Gigante; Domenico Paolo Emanuele Margiotta; Chiara Taffon; Rosario Cianci; Biagio Barbano; Marta Liberatori; Antonio Amoroso; Filippo Rossi Fanelli
Journal:  Intern Emerg Med       Date:  2015-02-27       Impact factor: 3.397

4.  Undertreatment of disease activity in systemic lupus erythematosus patients with endstage renal failure is associated with increased all-cause mortality.

Authors:  Anna Broder; Saakshi Khattri; Ruchika Patel; Chaim Putterman
Journal:  J Rheumatol       Date:  2011-09-01       Impact factor: 4.666

Review 5.  Lupus nephritis: an update.

Authors:  Tasnim F Imran; Frederick Yick; Suneet Verma; Christopher Estiverne; Chinonye Ogbonnaya-Odor; Srikanth Thiruvarudsothy; Alluru S Reddi; Neil Kothari
Journal:  Clin Exp Nephrol       Date:  2015-10-16       Impact factor: 2.801

Review 6.  Towards a pro-resolving concept in systemic lupus erythematosus.

Authors:  Sebastian Boeltz; Melanie Hagen; Jasmin Knopf; Aparna Mahajan; Maximilian Schick; Yi Zhao; Cornelia Erfurt-Berge; Jürgen Rech; Luis E Muñoz; Martin Herrmann
Journal:  Semin Immunopathol       Date:  2019-11-06       Impact factor: 9.623

Review 7.  Autoimmune heart disease: role of sex hormones and autoantibodies in disease pathogenesis.

Authors:  DeLisa Fairweather; Michelle A Petri; Michael J Coronado; Leslie T Cooper
Journal:  Expert Rev Clin Immunol       Date:  2012-03       Impact factor: 4.473

8.  Premature aortic atherosclerosis in systemic lupus erythematosus: a controlled transesophageal echocardiographic study.

Authors:  Carlos A Roldan; Joseph Joson; Janeen Sharrar; Clifford R Qualls; Wilmer L Sibbitt
Journal:  J Rheumatol       Date:  2009-12-01       Impact factor: 4.666

9.  Promoter variant of PIK3C3 is associated with autoimmunity against Ro and Sm epitopes in African-American lupus patients.

Authors:  Silvia N Kariuki; Beverly S Franek; Rachel A Mikolaitis; Tammy O Utset; Meenakshi Jolly; Andrew D Skol; Timothy B Niewold
Journal:  J Biomed Biotechnol       Date:  2010-07-04

10.  Understanding systemic lupus erythematosus patients' desired outcomes and their perceptions of the risks and benefits of using corticosteroids.

Authors:  X Ng; S dosReis; R Beardsley; L Magder; C D Mullins; M Petri
Journal:  Lupus       Date:  2017-08-31       Impact factor: 2.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.